Bionano Genomics, Inc. (BNGO) financial statements (2021 and earlier)

Company profile

Business Address 9540 TOWNE CENTRE DRIVE
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 3826 - Laboratory Analytical Instruments (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments381917817815
Cash and cash equivalents381917817815
Receivables3434665
Inventory, net of allowances, customer advances and progress billings3534333
Inventory3534333
Prepaid expense2   100
Other current assets0   010
Other undisclosed current assets 211   
Total current assets:47292517281824
Noncurrent Assets
Property, plant and equipment5432211
Intangible assets, net (including goodwill)99     
Goodwill77     
Intangible assets, net (excluding goodwill)12     
Other noncurrent assets0      
Total noncurrent assets:141232211
TOTAL ASSETS:60412719301925
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities91056666
Accounts payable3633334
Accrued liabilities6423333
Deferred revenue00000  
Debt 1414172011
Contract with customer, liability00
Total current liabilities:92520232678
Noncurrent Liabilities
Long-term debt and lease obligation1622  1919
Long-term debt, excluding current maturities1622  1919
Liabilities, other than long-term debt0000000
Deferred revenue00000  
Contract with customer, liability00
Other liabilities 0  000
Total noncurrent liabilities:1622001919
Total liabilities:25272123272727
Stockholders' equity
Stockholders' equity attributable to parent35156(4)4(7)(1)
Common stock0000000
Additional paid in capital1791471271091068787
Accumulated deficit(144)(132)(121)(113)(103)(95)(88)
Total stockholders' equity:35156(4)4(7)(1)
TOTAL LIABILITIES AND EQUITY:60412719301925

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Revenues4211332
Cost of revenue
(Cost of Goods and Services Sold)
(3)(1)(1)(1)(2)(2)(2)
Gross profit:1110111
Operating expenses(12)(11)(8)(10)(8)(7)(7)
Operating loss:(11)(10)(7)(10)(7)(6)(7)
Nonoperating expense(1)(1)(1)(1)(1)(1)(1)
Other nonoperating income (expense) 0(0)01(0)(0)
Interest and debt expense(1)(1)(1)(1)(0)(1)(1)
Loss from continuing operations before equity method investments, income taxes:(12)(11)(9)(11)(8)(7)(8)
Other undisclosed income from continuing operations before income taxes1111011
Loss from continuing operations before income taxes:(12)(11)(8)(11)(8)(6)(8)
Income tax expense (benefit)0(0)(0)(0)(0)(0)(0)
Net loss available to common stockholders, diluted:(12)(11)(8)(11)(8)(6)(8)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(12)(11)(8)(11)(8)(6)(8)
Comprehensive loss, net of tax, attributable to parent:(12)(11)(8)(11)(8)(6)(8)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: